Neoadjuvant immunochemoradiotherapy in esophageal squamous cell carcinoma: an updated narrative review

Read full text Summarise with VIRAT
Authors: Pengyu Luo, Jiahua Lyu, Xuefeng Leng
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Background and Objective: Esophageal squamous cell carcinoma (ESCC) is a deadly malignancy with poor prognosis for locally advanced disease. The advent of immune checkpoint inhibitors has transformed the therapeutic landscape. This review examines current evidence on neoadjuvant immunotherapy combined with chemoradiotherapy in ESCC, focusing on treatment sequencing, efficacy, safety, and future directions. Methods: We searched the PubMed and CNKI databases from January 2000 to March 2026 to identify published studies on the current use of neoadjuvant immunotherapy combined with chemoradiotherapy in ESCC, with language restrictions (English and Chinese only). Key Content and Findings: This review aims to integrate current evidence on neoadjuvant immunochemoradiotherapy in ESCC with focus on treatment sequencing, stage-specific efficacy, and emerging biomarkers. This integrated approach yielded substantial clinical benefits: pathological complete response (pCR) rates of 37–60% and 1-year overall survival (OS) rates of approximately 80% in resectable disease, representing a meaningful improvement over historical outcomes; for initially unresectable disease, sequential strategies enable conversion surgery in up to 66.7% of patients, with pCR reaching 65% in resected specimens. In metastatic ESCC, consolidative radiotherapy added to first-line immunochemotherapy prolongs median OS by 7–10 months. The safety profile was manageable, with predominantly hematologic and immune-related adverse events that rarely compromise surgical schedules. However, esophageal fistula (≈10% in heavily pretreated patients) requires vigilance. Beyond confirming concurrent regimen efficacy, emerging evidence suggests sequential approaches utilizing induction chemoimmunotherapy prior to chemoradiotherapy followed by maintenance immunotherapy may offer distinct advantages by enabling early systemic micro-metastatic control and sustaining long-term immune surveillance. Dynamic biomarkers (circulating tumor DNA clearance, tertiary lymphoid structures) outperform static programmed cell death ligand 1 (PD-L1) expression in predicting response. Conclusions: Neoadjuvant immunochemoradiotherapy represents a rapidly evolving paradigm for locally advanced ESCC, achieving pCR rates of 37–60% in operable disease and enabling conversion surgery in initially unresectable patients. While concurrent regimens demonstrate synergistic potential, emerging evidence supports sequential strategies, particularly for unresectable or advanced disease. However, most evidence derives from phase II trials; long-term survival benefits require validation in phase III trials with extended follow-up. Future directions include biomarker-driven adaptive strategies, standardized multidisciplinary management, and toxicity mitigation.

Fields of Study & Subjects

Esophageal Cancer Research and Treatment Gastric Cancer Management and Outcomes Head and Neck Cancer Studies

Publication details

Journal / source
Annals of Esophagus
Volume
9
Pages
6–6
Publication date
1 March 2026
Language
EN